Barriers to HCV micro-elimination in a cohort of people living with HIV (PLWH)
To achieve the World Health Organization goal of hepatitis C virus (HCV) eradication, barriers to treatment should be investigated and overcome. The aim of this study was to identify those barriers and describe the strategies adopted to achieve HCV micro-elimination in a cohort of coinfected people living with HIV (PLWH-HCV). Adult PLWH-HCV followed at our hospital with detectable serum HCV-RNA in 2018 were enrolled. After a three-year follow-up, barriers to HCV treatment were investigated and strategies to overcome them were described. Of 492 PLWH-HCV seen in 2018, 29 (5.9%) had detectable serum HCV-RNA. Eight out of 29 (27.6%) were excluded because they were already under treatment, while 2 others were excluded because they moved to other outpatient clinics. Among the remaining 19 study participants, the most common barriers to treatment were poor adherence to therapies and follow-up visits (n=9, 47%), recent HCV diagnosis awaiting proper staging (n=3, 16%) and treatment hesitancy (n=2, 10%). During the following three years, direct-acting antivirals (DAAs) treatment was completed in 11/19 (58%) cases, with achievement of sustained virological response in 100% of cases. For the remaining cases, 2/19 (10.5%) were lost to follow-up, 2/19 (10.5%) died before treatment initiation and 4/19 (21.0%) are still awaiting treatment. Despite 3 years of effort, HCV micro-elimination has not been achieved at our center. We observed that poor adherence and treatment hesitancy were the main barriers to treatment. Strategies addressing these issues need to be implemented.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
The new microbiologica - 46(2023), 3 vom: 19. Sept., Seite 246-251 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bartalucci, Claudia [VerfasserIn] |
|---|
| Themen: |
63231-63-0 |
|---|
| Anmerkungen: |
Date Completed 26.09.2023 Date Revised 26.09.2023 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM362438986 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362438986 | ||
| 003 | DE-627 | ||
| 005 | 20231226091239.0 | ||
| 007 | tu | ||
| 008 | 231226s2023 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1208.xml |
| 035 | |a (DE-627)NLM362438986 | ||
| 035 | |a (NLM)37747468 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bartalucci, Claudia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Barriers to HCV micro-elimination in a cohort of people living with HIV (PLWH) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 26.09.2023 | ||
| 500 | |a Date Revised 26.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a To achieve the World Health Organization goal of hepatitis C virus (HCV) eradication, barriers to treatment should be investigated and overcome. The aim of this study was to identify those barriers and describe the strategies adopted to achieve HCV micro-elimination in a cohort of coinfected people living with HIV (PLWH-HCV). Adult PLWH-HCV followed at our hospital with detectable serum HCV-RNA in 2018 were enrolled. After a three-year follow-up, barriers to HCV treatment were investigated and strategies to overcome them were described. Of 492 PLWH-HCV seen in 2018, 29 (5.9%) had detectable serum HCV-RNA. Eight out of 29 (27.6%) were excluded because they were already under treatment, while 2 others were excluded because they moved to other outpatient clinics. Among the remaining 19 study participants, the most common barriers to treatment were poor adherence to therapies and follow-up visits (n=9, 47%), recent HCV diagnosis awaiting proper staging (n=3, 16%) and treatment hesitancy (n=2, 10%). During the following three years, direct-acting antivirals (DAAs) treatment was completed in 11/19 (58%) cases, with achievement of sustained virological response in 100% of cases. For the remaining cases, 2/19 (10.5%) were lost to follow-up, 2/19 (10.5%) died before treatment initiation and 4/19 (21.0%) are still awaiting treatment. Despite 3 years of effort, HCV micro-elimination has not been achieved at our center. We observed that poor adherence and treatment hesitancy were the main barriers to treatment. Strategies addressing these issues need to be implemented | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a DAAs | |
| 650 | 4 | |a Hepatitis C virus | |
| 650 | 4 | |a barriers | |
| 650 | 4 | |a human immunodeficiency virus | |
| 650 | 4 | |a micro-elimination | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a RNA |2 NLM | |
| 650 | 7 | |a 63231-63-0 |2 NLM | |
| 700 | 1 | |a Taramasso, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Nicolini, Laura Ambra |e verfasserin |4 aut | |
| 700 | 1 | |a Magnasco, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Labate, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Vena, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Mora, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Giacomini, Mauro |e verfasserin |4 aut | |
| 700 | 1 | |a Bassetti, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Di Biagio, Antonio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The new microbiologica |d 1993 |g 46(2023), 3 vom: 19. Sept., Seite 246-251 |w (DE-627)NLM074818287 |x 1121-7138 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2023 |g number:3 |g day:19 |g month:09 |g pages:246-251 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2023 |e 3 |b 19 |c 09 |h 246-251 | ||